These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9193313)

  • 21. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 23. Vigabatrin-associated retinal cone system dysfunction.
    Roubertie A; Bellet H; Echenne B
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855564
    [No Abstract]   [Full Text] [Related]  

  • 24. Vigabatrin-associated retinal cone system dysfunction.
    Brigell MG
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855563
    [No Abstract]   [Full Text] [Related]  

  • 25. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vigabatrin-associated retinal cone system dysfunction.
    Beck RW
    Neurology; 1998 Dec; 51(6):1778-9; author reply 1779-81. PubMed ID: 9855562
    [No Abstract]   [Full Text] [Related]  

  • 27. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

  • 30. Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?
    Durnian JM; Clearkin LG
    Eye (Lond); 2008 Apr; 22(4):559-63. PubMed ID: 17401319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 32. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents.
    Baulac M; Nordmann JP; Lanoé Y
    Lancet; 1998 Aug; 352(9127):546. PubMed ID: 9716066
    [No Abstract]   [Full Text] [Related]  

  • 36. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vigabatrin and visual fields defects].
    Jensen K
    Ugeskr Laeger; 2001 Jan; 163(2):184. PubMed ID: 11379251
    [No Abstract]   [Full Text] [Related]  

  • 38. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.
    Krauss GL; Johnson MA; Miller NR
    Neurology; 1998 Mar; 50(3):614-8. PubMed ID: 9521245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vigabatrin-associated visual field loss.
    Fecarotta C; Sergott RC
    Int Ophthalmol Clin; 2012; 52(3):87-94, xii. PubMed ID: 22668542
    [No Abstract]   [Full Text] [Related]  

  • 40. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
    Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
    Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.